DocMorris posts strong first quarter with revenue up 10.7% By Investing.com

DocMorris reported Q1 revenue growth of 10.7% in local currency to CHF318.1m, with German prescription sales up 26.4% year-over-year to CHF68.1m and active users rising to 12.6m. Adjusted EBITDA improved by nearly CHF10m year-over-year to negative CHF6.3m, while the company reaffirmed 2026 guidance for mid-single-digit to low-teens revenue growth and EBITDA of negative CHF10m to negative CHF25m. Management also said Rx growth accelerated further in March, supporting a constructive near-term trend.

Analysis

DocMorris is showing the kind of early inflection that matters more for equity underwriting than headline growth: prescription mix is improving, and the co-pay incentive appears to be pulling forward share gains in Germany rather than merely lifting low-margin traffic. That matters because Rx scale has a much cleaner path to operating leverage than non-Rx commerce; if the March acceleration persists, the market likely underestimates how quickly fixed-cost absorption can compress losses over the next 2-3 quarters.

The second-order winner may be adjacent digital healthcare infrastructure, not just the pharmacy itself. Telemedicine, retail media, and marketplace monetization are growing much faster than core commerce, which suggests DocMorris is increasingly becoming a traffic-and-distribution platform; that can pressure smaller online pharmacies and traditional brick-and-mortar chains if reimbursement incentives continue to favor online fulfillment. The real competitive risk is that incumbents respond with their own subsidy programs, turning this into a margin arms race where the gross profit pool is preserved but economic profit is delayed.

The key risk is policy and incentive durability. If the co-pay bonus rollout is temporary, the Q1 acceleration could normalize quickly, making the path to Q4 EBITDA break-even more dependent on mix and cost control than top-line momentum. On the other hand, if management can sustain low-double-digit Rx growth through the summer, the market may re-rate the name on a 2027 free-cash-flow break-even story rather than a simple loss-making retailer, which is a materially different valuation framework.

Contrarian view: the stock may be too cheap if investors are anchoring on legacy negative EBITDA and missing the option value of a scaled German Rx platform with improving user engagement. But the consensus may also be overestimating the durability of incentive-led demand; in this model, the next 90 days are more important than the next 12 months, because any deceleration would quickly expose how much of the improvement is promotional versus structural.

Key Decisions for Investors

• Initiate a tactical long in DOCM for 4-8 weeks into the next operating update; thesis is continued March-like Rx acceleration and multiple expansion if users and German Rx remain above mid-teens growth, with a stop if growth reverts to low single digits.
• Pair trade: long DOCM / short a basket of brick-and-mortar European pharmacy/health retail exposure over 2-3 months; the spread should work if online prescription share continues to take incremental wallet share and management confirms Q4 EBITDA breakeven visibility.
• Use call spreads rather than outright equity for DOCM if liquidity permits: buy 3-6 month upside calls financed by selling further out-of-the-money strikes, targeting a 2:1 to 3:1 payoff if the market starts discounting 2027 FCF break-even earlier.
• Watch for policy reversal or incentive rollback; if co-pay support fades, fade the move and consider taking profits quickly, since the downside is a de-rating back to 'loss-making growth story' status within 1-2 quarters.